JP2000510451A - 成長ホルモンの使用 - Google Patents
成長ホルモンの使用Info
- Publication number
- JP2000510451A JP2000510451A JP09537020A JP53702097A JP2000510451A JP 2000510451 A JP2000510451 A JP 2000510451A JP 09537020 A JP09537020 A JP 09537020A JP 53702097 A JP53702097 A JP 53702097A JP 2000510451 A JP2000510451 A JP 2000510451A
- Authority
- JP
- Japan
- Prior art keywords
- medicament
- treatment
- rhgh
- insulin
- abdominal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 代謝性症候群の治療のための医薬を製造するための成長ホルモン、好まし くはヒト成長ホルモン又はその類似体の使用。 2. インスリン非依存性糖尿病の予防及び治療のための医薬を製造するための 成長ホルモン、好ましくはヒト成長ホルモン又はその類似体の使用。 3. 当該医薬が腹部/内臓肥満症の治療のためである請求項1又は2に記載の 使用。 4. 当該医薬がインスリン感受性の増加のためであるいずれかの先行請求項に 記載の使用。 5. 当該医薬がインスリン抵抗の減少のためであるいずれかの先行請求項に記 載の使用。 6. 当該医薬が少なくとも6週、好ましくは6ヶ月以上、そして好ましくは9 ヶ月以上の治療のためであるいずれかの先行請求項に記載の使用。 7. 当該医薬が全体脂肪質量の減少のためであるいずれかの先行請求項に記載 の使用。 8. 当該医薬が腹部/内臓肥満症のヒトにおける全体脂肪の 減少のためであるいずれかの先行請求項に記載の使用。 9. 当該医薬が内臓脂肪組織域のためであるいずれかの先行請求項に記載の使 用。 10. 当該医薬がトリグリセリドの血清濃度の減少のためであるいずれかの先 行請求項に記載の使用。 11. 当該医薬が拡張期血圧の減少のためであるいずれかの先行請求項に記載 の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9601397-4 | 1996-04-12 | ||
SE9601397A SE9601397D0 (sv) | 1996-04-12 | 1996-04-12 | Use of growth hormone |
PCT/SE1997/000601 WO1997038709A1 (en) | 1996-04-12 | 1997-04-10 | Use of growth hormone |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2000510451A true JP2000510451A (ja) | 2000-08-15 |
Family
ID=20402176
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09537020A Pending JP2000510451A (ja) | 1996-04-12 | 1997-04-10 | 成長ホルモンの使用 |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0935469B1 (ja) |
JP (1) | JP2000510451A (ja) |
AT (1) | ATE228007T1 (ja) |
CA (1) | CA2250907A1 (ja) |
DE (1) | DE69717301T2 (ja) |
DK (1) | DK0935469T3 (ja) |
ES (1) | ES2187771T3 (ja) |
NZ (1) | NZ332105A (ja) |
PT (1) | PT935469E (ja) |
SE (1) | SE9601397D0 (ja) |
WO (1) | WO1997038709A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087090A (en) * | 1997-02-25 | 2000-07-11 | Celtrix Pharmaceuticals, Inc. | Methods for predicting drug response |
AU737065B2 (en) * | 1997-07-04 | 2001-08-09 | Pharmacia Ab | Use of growth hormone in compositions for treating insulin resistance in the heart and for enhancing protein kinase B (PKB) activity |
CA2352316A1 (en) * | 1998-11-26 | 2000-06-02 | Auckland Uniservices Limited | Treatment of hypertension |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
AU1130501A (en) * | 1999-11-03 | 2001-05-14 | Novo Nordisk A/S | Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety |
SE0000837D0 (sv) | 2000-03-13 | 2000-03-13 | Pharmacia & Upjohn Ab | New use |
AU2006200127B2 (en) * | 2000-03-13 | 2007-10-25 | Pfizer Inc. | Use of growth hormone in low dose |
ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
US20040248788A1 (en) * | 2001-07-06 | 2004-12-09 | Vickers Mark Hedley | Hypertenson treatment |
US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
US7833964B2 (en) | 2003-08-21 | 2010-11-16 | Tercica, Inc. | Methods of reducing visceral fat by increasing levels of insulin-like growth factor-I (IGF-I) |
US8440695B2 (en) * | 2005-11-09 | 2013-05-14 | St Jude Children's Research Hospital | Use of chloroquine to treat metabolic syndrome |
CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
EP2118080B1 (en) | 2007-02-09 | 2016-08-31 | Ocera Therapeutics, Inc. | Macrocyclic ghrelin receptor modulators and methods of using the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5268277A (en) * | 1987-08-07 | 1993-12-07 | Eniricerche S.P.A. | Method for the preparation of human growth hormone |
-
1996
- 1996-04-12 SE SE9601397A patent/SE9601397D0/xx unknown
-
1997
- 1997-04-10 AT AT97919856T patent/ATE228007T1/de not_active IP Right Cessation
- 1997-04-10 WO PCT/SE1997/000601 patent/WO1997038709A1/en active IP Right Grant
- 1997-04-10 EP EP97919856A patent/EP0935469B1/en not_active Expired - Lifetime
- 1997-04-10 CA CA002250907A patent/CA2250907A1/en not_active Abandoned
- 1997-04-10 ES ES97919856T patent/ES2187771T3/es not_active Expired - Lifetime
- 1997-04-10 NZ NZ332105A patent/NZ332105A/xx unknown
- 1997-04-10 DK DK97919856T patent/DK0935469T3/da active
- 1997-04-10 PT PT97919856T patent/PT935469E/pt unknown
- 1997-04-10 JP JP09537020A patent/JP2000510451A/ja active Pending
- 1997-04-10 DE DE69717301T patent/DE69717301T2/de not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0935469B1 (en) | 2002-11-20 |
DE69717301D1 (de) | 2003-01-02 |
DE69717301T2 (de) | 2003-09-04 |
DK0935469T3 (da) | 2003-03-17 |
WO1997038709A1 (en) | 1997-10-23 |
PT935469E (pt) | 2003-03-31 |
EP0935469A1 (en) | 1999-08-18 |
SE9601397D0 (sv) | 1996-04-12 |
NZ332105A (en) | 2000-03-27 |
ES2187771T3 (es) | 2003-06-16 |
ATE228007T1 (de) | 2002-12-15 |
CA2250907A1 (en) | 1997-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goran et al. | Relation between visceral fat and disease risk in children and adolescents | |
US20220257591A1 (en) | Methods for Treating Visceral Fat Conditions | |
Beshyah et al. | Replacement treatment with biosynthetic human growth hormone in growth hormone‐deficient hypopituitary adults | |
Burman et al. | Endocrine dysfunction in Prader-Willi syndrome: a review with special reference to GH | |
Jørgensen et al. | Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance | |
Aversa et al. | Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome | |
Goodpaster et al. | Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. | |
Mårin et al. | Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone | |
Overgaard et al. | Nasal calcitonin for treatment of established osteoporosis | |
Rosén et al. | Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment: a review paper | |
Al‐Shoumer et al. | Elevated leptin concentrations in growth hormone‐deficient hypopituitary adults | |
Salway et al. | Effect of myo-inositol on peripheral-nerve function in diabetes | |
US6562790B2 (en) | Hormone therapy methods and hormone products for abating coronary artery blockage | |
JP2000510451A (ja) | 成長ホルモンの使用 | |
EA004573B1 (ru) | Способы лечения женщин в постклимактерическом состоянии с применением ультранизких доз эстрогена | |
Ehrnborg et al. | Supraphysiological growth hormone: less fat, more extracellular fluid but uncertain effects on muscles in healthy, active young adults | |
Vahl et al. | The favourable effects of growth hormone (GH) substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study | |
Gertner | Effects of growth hormone on body fat in adults | |
JP2003530349A (ja) | 皮膚病用の使用方法及び皮膚病用薬剤 | |
Tanriverdi et al. | Effects of 18-month of growth hormone (GH) replacement therapy in patients with Sheehan’s syndrome | |
Sherwin et al. | Metabolic effects of insulin-like growth factor I in normal humans | |
Shieh et al. | Improvement in metabolic risk factors for coronary heart disease associated with cilazapril treatment | |
Postma et al. | Improvements in body composition after 4 years of growth hormone treatment in adult-onset hypopituitarism compared to age-matched controls | |
Jain et al. | Pathogenesis and treatment of human immunodeficiency virus lipodystrophy | |
US6846800B1 (en) | Method for treating a patient having metabolic syndrome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040402 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070227 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070521 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070709 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070827 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20071005 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20071012 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20071012 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20090217 |